Skip to content

Ehealth: Second Life Impacts Diabetes Education & Self-Management

Ehealth: Second Life Impacts Diabetes Education & Self-Management

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01186965
Acronym
SLIDES
Enrollment
20
Registered
2010-08-23
Start date
2011-01-31
Completion date
2012-08-31
Last updated
2015-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Diabetes, Second Life, virtual community, diabetes education, diabetes support group

Brief summary

The purpose of this study is to to develop and evaluate the feasibility, usability, and effect of participation in SLIDES (a virtual diabetes community in Second Life) for providing interactive diabetes education, support, and resources.

Interventions

BEHAVIORALeHealth program in the Virtual Environment (VE) platform Second Life

determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* current Duke Endocrinology patient * are between 21 and 75 years old * are able to speak and read English * are computer literate (have used a computer for at least 6 months) * understand how to use the Internet (have accessed the Internet on at least 6 occasions) * have access to a computer with a non-dial-up Internet connection in a private location (home) * are mentally capable of informed consent * are reachable by telephone * have no pre-existing medical condition(s) or severe diabetes related complications that would interfere with study participation (i.e., physical activity) or measures (e.g., renal failure, Stage III hypertension, severe orthopedic conditions or joint replacement scheduled within 6 months, paralysis, bleeding disorders, cancer, or receipt of pharmacologic doses of anti-coagulant medications \[warfarin\]) * are able to travel to Duke University Medical Center (DUMC) for follow-up appointments.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Perceived Usefulness3 and 6 months
Perceived Ease of Use3 and 6 months
Process dataJanuary 2011 through May 2012

Secondary

MeasureTime frame
Demographicsbaseline
Metabolic Indicatorsbaseline, 3 months, 6 months
Diabetes knowledgebaseline, 3 months, 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026